Gordienko S M, Lasitsa O I, Misharina Zh A, Fedorchuk A G
Ter Arkh. 1995;67(6):32-8.
Children and adults with chronic ENT and bronchopulmonary infections took ribomunyl tablets (Pierre Fabre) under immunological control. Even a 3 week course led to obvious clinical improvement of their condition in acute stage. Investigation of populations and subpopulations of lymphocytes showed that ribomunyl mainly increases the number of CD3+, CD3+4+, CD3-/16+56-, CD4+25+, CD4+69+, CD56+25+. CD56-25+ and CD8-38+ cells that is increased the number of T-, T-n and NK-cells and also increased expression on T-n and NK-cells of activation antigens. An increase in quantity and activation of these cells was more expressed in patients with initially smaller number of these cells and correlated with the treatment efficacy. Ribomunyl enhanced effector function of NK-cells, phagocytes (monocytes and granulocytes), this activation being more in patients with marked clinical effect. Ribomunyl appeared effective in Chernobyl accident victims also. A long-term course of ribomunyl (6 months) showed better clinical effect when compared to 3-week course.
患有慢性耳鼻喉和支气管肺部感染的儿童及成人在免疫控制下服用了力保美达片（皮尔法伯公司生产）。即使是为期3周的疗程也能使他们在急性期的病情得到明显的临床改善。对淋巴细胞群体和亚群体的研究表明，力保美达主要增加CD3 +、CD3 + 4 +、CD3 - / 16 + 56 -、CD4 + 25 +、CD4 + 69 +、CD56 + 25 +、CD56 - 25 +和CD8 - 38 +细胞的数量，即增加T细胞、T辅助细胞和自然杀伤细胞的数量，同时也增加T辅助细胞和自然杀伤细胞上激活抗原的表达。这些细胞数量的增加和激活在最初这些细胞数量较少的患者中表现得更为明显，且与治疗效果相关。力保美达增强了自然杀伤细胞、吞噬细胞（单核细胞和粒细胞）的效应功能，这种激活在临床效果显著的患者中更为明显。力保美达对切尔诺贝利事故受害者似乎也有效。与3周疗程相比，力保美达的长期疗程（6个月）显示出更好的临床效果。
